LGND FY 2025 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$268M+60.4% YoY

Gross Profit

$261M97.5% margin

Operating Income

$47M17.6% margin

Net Income

$124M46.4% margin

EPS (Diluted)

$6.13

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$49M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$543M

Stockholders' Equity

$1.0B

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$268M	$167M	+60.4%
Gross Profit	$261M	$156M	+67.6%
Operating Income	$47M	-$23M	+308.8%
Net Income	$124M	-$4M	+3186.6%